Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis.
Biological therapy
Refractory disease
Rheumatoid arthritis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
09 12 2020
09 12 2020
Historique:
received:
27
04
2020
accepted:
15
10
2020
entrez:
10
12
2020
pubmed:
11
12
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Biological therapies have improved the clinical course and quality of life of rheumatoid arthritis (RA) patients. Despite the availability and effectiveness of these treatments, some patients experience multiple failures to biologic disease-modifying antirheumatic drugs (bDMARDs), constituting a particular challenge to clinicians. This study aims to determine the percentage of rheumatoid arthritis (RA) patients who fail to respond to subsequent bDMARDs, describe their characteristics, and identify specific baseline and early features during the first bDMARD as possible predictors of consecutive multiple bDMARD failure. This is a longitudinal study involving RA patients from the prospective biological cohort drawn from the La Paz University Hospital RA Registry (RA-Paz), starting a bDMARD during the years 2000 to 2019. Patients who presented insufficient response (due to primary or secondary inefficacy) to at least three bDMARDs or two bDMARDs with different mechanism of action were considered multi-refractory (MR-patients). Patients who achieved low disease activity or remission (by DAS-28) with the first bDMARD and maintained this over a follow-up period of at least 5 years were considered non-refractory (NR-patients). A total of 41 out of 402 (10%) patients were MR-patients and 71 (18%) NR-patients. In the multivariate analysis, the presence of erosions, younger age, higher baseline DAS-28 and mostly achieving delta-DAS < 1.2 after 6 months of the first bDMARD (OR 11.12; 95% CI 3.34-26.82) were independently associated with being MR-patients to bDMARDs. In our cohort, 10% of patients with RA were observed to have multi-refractoriness to bDMARDs. This study supports the contention that younger patients with erosive disease and especially the early absence of clinical response to the first bDMARDs are predictors of multi-refractoriness to consecutive biologics. Hence, patients with these characteristics should be monitored more closely and may benefit from personalized treatments.
Sections du résumé
BACKGROUND
Biological therapies have improved the clinical course and quality of life of rheumatoid arthritis (RA) patients. Despite the availability and effectiveness of these treatments, some patients experience multiple failures to biologic disease-modifying antirheumatic drugs (bDMARDs), constituting a particular challenge to clinicians.
OBJECTIVES
This study aims to determine the percentage of rheumatoid arthritis (RA) patients who fail to respond to subsequent bDMARDs, describe their characteristics, and identify specific baseline and early features during the first bDMARD as possible predictors of consecutive multiple bDMARD failure.
METHODS
This is a longitudinal study involving RA patients from the prospective biological cohort drawn from the La Paz University Hospital RA Registry (RA-Paz), starting a bDMARD during the years 2000 to 2019. Patients who presented insufficient response (due to primary or secondary inefficacy) to at least three bDMARDs or two bDMARDs with different mechanism of action were considered multi-refractory (MR-patients). Patients who achieved low disease activity or remission (by DAS-28) with the first bDMARD and maintained this over a follow-up period of at least 5 years were considered non-refractory (NR-patients).
RESULTS
A total of 41 out of 402 (10%) patients were MR-patients and 71 (18%) NR-patients. In the multivariate analysis, the presence of erosions, younger age, higher baseline DAS-28 and mostly achieving delta-DAS < 1.2 after 6 months of the first bDMARD (OR 11.12; 95% CI 3.34-26.82) were independently associated with being MR-patients to bDMARDs.
CONCLUSIONS
In our cohort, 10% of patients with RA were observed to have multi-refractoriness to bDMARDs. This study supports the contention that younger patients with erosive disease and especially the early absence of clinical response to the first bDMARDs are predictors of multi-refractoriness to consecutive biologics. Hence, patients with these characteristics should be monitored more closely and may benefit from personalized treatments.
Identifiants
pubmed: 33298140
doi: 10.1186/s13075-020-02354-1
pii: 10.1186/s13075-020-02354-1
pmc: PMC7724866
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Products
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
284Références
Arthritis Care Res (Hoboken). 2014 Feb;66(2):173-9
pubmed: 23982986
Ann Rheum Dis. 2010 Feb;69(2):387-93
pubmed: 19416802
Clin Rheumatol. 2019 Mar;38(3):949-954
pubmed: 30402698
Arthritis Rheum. 2004 Apr;50(4):1051-65
pubmed: 15077287
Joint Bone Spine. 2014 Jan;81(1):37-40
pubmed: 23731638
Curr Pharm Des. 2015;21(2):170-81
pubmed: 25163741
Arthritis Rheumatol. 2017 Aug;69(8):1566-1575
pubmed: 28425173
Ann Rheum Dis. 2018 Oct;77(10):1405-1412
pubmed: 29980575
Arthritis Res Ther. 2013 Dec 24;15(6):R221
pubmed: 24365061
Rheumatology (Oxford). 2018 Jul 1;57(7):1135-1144
pubmed: 29029308
Arthritis Rheumatol. 2016 Jan;68(1):1-26
pubmed: 26545940
Ann Rheum Dis. 2018 Jul;77(7):966-969
pubmed: 29588276
Semin Arthritis Rheum. 2019 Oct;49(2):211-217
pubmed: 30799033
Ann Rheum Dis. 2018 Dec;77(12):1705-1709
pubmed: 30194273
Arthritis Rheum. 2000 Jan;43(1):22-9
pubmed: 10643696
Drugs. 2020 Jun;80(9):849-857
pubmed: 32361822
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Arthritis Rheum. 2010 Jan;62(1):22-32
pubmed: 20039405
Ann Rheum Dis. 2016 Jan;75(1):3-15
pubmed: 25969430
Rheumatology (Oxford). 2020 Jul 1;59(7):1709-1714
pubmed: 31714580
Arthritis Rheum. 2006 Mar;54(3):702-10
pubmed: 16508926
Arthritis Rheum. 2007 Oct;56(10):3226-35
pubmed: 17907167
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Rheumatology (Oxford). 2014 Sep;53(9):1664-8
pubmed: 24729445
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Arthritis Rheum. 2007 Jan;56(1):13-20
pubmed: 17195186
Arthritis Care Res (Hoboken). 2020 Jan;72(1):27-35
pubmed: 30474932